Empiriko
Empiriko is a biotech company focused on developing targeted radioligand therapies and antibody drug conjugates for cancer, as well as next-generation point-of-care diagnostics. Their integrated technology platform leverages advances in medicinal chemistry, immunology, engineering, and computational modeling to connect their radioligand therapies and antibody drug conjugates with a disease/drug monitoring device. This creates a disruptive model for personalized care, aiming to revolutionize treatment and improve patient outcomes. Key technologies include R*ECL-AI-M™, a platform for targeted radioligand therapy, and PMF™, a device for real-time disease and drug monitoring. Their pipeline includes therapies for prostate, GEP-NET, and ovarian cancers.
Empiriko
Empiriko is a biotech company focused on developing targeted radioligand therapies and antibody drug conjugates for cancer, as well as next-generation point-of-care diagnostics. Their integrated technology platform leverages advances in medicinal chemistry, immunology, engineering, and computational modeling to connect their radioligand therapies and antibody drug conjugates with a disease/drug monitoring device. This creates a disruptive model for personalized care, aiming to revolutionize treatment and improve patient outcomes. Key technologies include R*ECL-AI-M™, a platform for targeted radioligand therapy, and PMF™, a device for real-time disease and drug monitoring. Their pipeline includes therapies for prostate, GEP-NET, and ovarian cancers.